Full history for every metric is available with a Kvantra account
Acticor Biotech SAS (ALACT.PA)
Key financial summary
Financials in EUR| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | €m | -20 | -12 | |||||
| Net profit | €m | -6 | -5 | -8 | -13 | -16 | -19 | -7 |
| EPS reported | € | -1.54 | -1.82 | |||||
| Operating cashflow per share | € | -1.08 | -1.08 | |||||
| Capex per share | € | 0.00 | 0.00 | |||||
| FCF per share | € | -1.08 | -1.08 | |||||
| Free cash flow | €m | -13 | -5 | |||||
| Net debt | €m | 2 | 2 | |||||
| Book value equity | €m | -5 | -5 | |||||
| Book value per share | € | -0.44 | -0.34 | |||||
| Number of shares | m | 12.07 | 15.76 | |||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -6.59 | -0.74 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -2.68 | -0.73 | |||||
| EV/EBITDA LTM | x | -2.07 | -1.76 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -53.26% | -617.81% | |||||
| FCF Yield | % | -37.26% | -137.86% | |||||
| Quality | ||||||||
| ROE | % | 350.84% | 493.38% | |||||
| ROIC | % | -1849.7% | -1849.7% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -2.22 | -0.75 | |||||
| Net Debt/EBITDA | x | -0.11 | -0.11 | |||||
| EBIT/Net interest | x | -9.42 | -9.42 | |||||
| Net debt/market cap | % | 5.68% | 61.67% | |||||
| Net debt/Equity | x | -0.37 | -0.46 | |||||
| Gross debt/equity | x | -1.11 | -1.37 | |||||
Company overview
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Acticor Biotech SAS (ALACT.PA)
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free